Literature DB >> 30997537

Pregnancy rate and outcome of pregnancies in long-term survivors of Hodgkin's lymphoma.

Francesco Gaudio1, Claudia Nardelli2, Paola Masciandaro2, Tommasina Perrone3, Filomena Emanuela Laddaga4, Paola Curci3, Raffaella Depalo2, Ettore Cicinelli2, Giorgina Specchia3.   

Abstract

Thanks to the increased number of young survivors of Hodgkin's lymphoma (HL), management of the pregnancies of women who have a history of exposure to chemotherapies and radiation therapy is becoming increasingly common. Many patients and clinicians are worried that pregnancy after the diagnosis of HL may increase the risk of relapse, despite a lack of empirical evidence to support such concerns. In the present study, we included 89 women diagnosed with HL between 2006 and 2015 under the age of 50 years, who were in complete remission and alive without relapse > 1 year after treatment. We determined the pregnancy rate, time to pregnancy, and the disease-free survival. We found no evidence of significant impairment of the fertility of female HL long-term survivors and no evidence that a pregnancy increases the relapse rate among women in remission from HL. Survivors of HL need to consider a range of factors when deciding on future reproduction.

Entities:  

Keywords:  Fertility; Hodgkin; Pregnancy

Mesh:

Substances:

Year:  2019        PMID: 30997537     DOI: 10.1007/s00277-019-03684-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  2 in total

1.  Involved Site Radiotherapy Extends Time to Premature Menopause in Infra-Diaphragmatic Female Hodgkin Lymphoma Patients - An Analysis of GHSG HD14- and HD17-Patients.

Authors:  Johannes Rosenbrock; Andrés Vásquez-Torres; Horst Mueller; Karolin Behringer; Matthias Zerth; Eren Celik; Jiaqi Fan; Maike Trommer; Philipp Linde; Michael Fuchs; Peter Borchmann; Andreas Engert; Simone Marnitz; Christian Baues
Journal:  Front Oncol       Date:  2021-05-25       Impact factor: 6.244

2.  Successful pregnancy and fetal outcome following previous treatment with pembrolizumab for relapsed Hodgkin's lymphoma.

Authors:  Alexandre Le-Nguyen; Ryan N Rys; Tina Petrogiannis-Haliotis; Nathalie A Johnson
Journal:  Cancer Rep (Hoboken)       Date:  2021-05-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.